BioAge Labs

BioAge Labs is a clinical-stage biotechnology startup aiming to develop novel targets and therapies for metabolic diseases by leveraging the biology of human aging. The company's proprietary platform, encompassing >65M molecular measurements over 45+ years of human aging, provides valuable insights into age-related diseases. The lead program, azelaprag, a potential first-in-class oral APJ agonist, is entering Phase 2 trials in combination with tirzepatide for treating obesity in older adults. The company's preclinical programs focus on key pathways in metabolic aging, leveraging insights from its discovery platform built on human longevity data. Founded in 2015 and based in the United States, BioAge Labs received a significant $170.00M Series D investment on February 13, 2024. The investors in this round include notable names such as Amgen Ventures, Longitude Capital, RA Capital Management, Andreessen Horowitz/a16z, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, Sands Capital Ventures, Cormorant Asset Management, and Lilly Ventures. Apart from its scientific endeavors, BioAge offers a comprehensive compensation package, health and wellness benefits, childcare and fertility benefits, and a 401(k) retirement savings plan. The company is committed to providing ample opportunities for career development and embraces diversity and differences in its workforce, affirming its commitment to being an equal opportunity employer.